Adenomatous Polyposis Coli Loss Controls Cell Cycle Regulators and Response to Paclitaxel

Emily M. Astarita[1,2], Camden A. Hoover[1,3], Sara M. Maloney[1,4], T. Murlidharan Nair[5], and Jenifer R. Prosperi[1,3,4,*]

[1]Harper Cancer Research Institute, South Bend, IN 46617, USA

[2] Department of Chemistry/Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA

[3] Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556, USA

[4] Indiana University School of Medicine – South Bend, Department of Biochemistry and Molecular Biology, South Bend, IN 46617, USA

[5] Indiana University – South Bend, South Bend, IN 46615, USA

Emily M. Astarita: emily@astarita.me
Camden A. Hoover: choover3@nd.edu
Sara M. Maloney: smalone3@nd.edu
T. Murlidharan Nair: mnair@iusb.edu
*Jenifer R. Prosperi (Corresponding author): jrprospe@iupui.edu, (574) 631-4002

Running Title: APC controls paclitaxel response

The authors declare no potential conflicts of interest.

Abstract

Adenomatous Polyposis Coli (APC) is lost in approximately 70% of sporadic breast cancers, with an inclination towards triple negative breast cancer (TNBC). TNBC is treated with traditional chemotherapy, such as paclitaxel (PTX); however, tumors often develop drug resistance. We previously created APC knockdown cells (APC shRNA1) using the human TNBC cells, MDA-MB-157, and showed that APC loss induces PTX resistance. To understand the mechanisms behind APC-mediated PTX response, we performed cell cycle analysis and analyzed cell cycle related proteins. Cell cycle analysis indicated increased G2/M population in PTX-treated APC shRNA1 cells compared to PTX-treated controls, suggesting that APC expression does not alter PTX-induced G2/M arrest. We further studied the subcellular localization of the G2/M transition proteins, cyclin B1 and CDK1. The APC shRNA1 cells had increased CDK1, which was preferentially localized to the cytoplasm, and increased CDK6. RNA-sequencing was performed to gain a global understanding of changes downstream of APC loss and identified a broad mis-regulation of cell cycle-related genes in APC shRNA1 cells. Our studies are the first to show an interaction between APC and taxane response in breast cancer. The implications include designing combination therapy to re-sensitize APC-mutant breast cancers to taxanes using the specific cell cycle alterations.

Key words: APC, breast cancer, chemoresistance, paclitaxel, cell cycle

INTRODUCTION

Breast cancer accounts for 30% of all new cancer diagnoses in women and is the leading cause of death for women between the ages of 20 and 59 years. Compared to other cancers, the genetic variability that is seen in breast cancer complicates treatment. There exist different subtypes of breast cancer tumors, characterized by their expression of functional receptors. The major subtypes of breast cancer include luminal A, luminal B, HER2 enriched and triple negative. Both luminal A and B are estrogen receptor (ER) positive, while HER2 enriched is human epidermal growth factor 2 receptor (HER2) positive. These hormone responsive subtypes can be treated with more specific therapies. Triple negative breast cancer (TNBC) is a subtype that is named by its lack of all three functioning receptors that are up-regulated in other subtypes: HER2, ER, and progesterone receptor (PR). For this reason, TNBC patients have limited treatment options as the lack of receptors disallows the use of more targeted therapies. As a result, they are treated with traditional chemotherapies, such as taxanes, platinums, and anthracyclines. Despite initial positive response, TNBCs often develop resistance and/or tumor relapse. Paclitaxel (PTX) is a taxane used for TNBC, which is well established to induce mitotic arrest due to activation of the spindle assembly checkpoint [1]. PTX arrests cells through interfering with the treadmilling function of microtubules (MTs), necessary for chromosome segregation and cell division, and inducing changes in cell cycle proteins that are important for mitotic function. While the mechanism of action of PTX is well characterized, PTX resistance remains less explicated.

Adenomatous Polyposis Coli (APC) is a multi-domain protein and acts as a negative regulator to the Wnt/β-catenin signaling pathway to control gene expression, cell proliferation, and differentiation [2]. APC also functions independently of β-catenin in the regulation of MT stability, DNA repair, and cytoskeletal organization through mechanisms that are not fully understood [3]. *APC* is mutated or hypermethylated in up to 70% of sporadic breast tumors with an inclination towards TNBCs [4]. In fact, breast cancers lacking just two of the three hormone receptors see a significant increase in APC methylation compared to tumors with functioning hormone receptors [5]. The uninvestigated roles of APC indicate that it may have significant implications on the efficacy of breast cancer treatments.

Findings have demonstrated that APC loss contributes to chemotherapy resistance through disruption of mitotic spindle, enhancing DNA repair, and alterations in expression and activity of ATP-dependent binding cassette transporters [6-8]. In an *in vivo* model of APC loss, cells become less responsive to Taxol treatments. Fewer APC mutant cells went into mitotic arrest after Taxol treatment compared to the wild type cells, and Taxol failed to induce apoptosis in APC deficient cells [6]. In addition, our lab previously showed that APC loss increases PTX resistance in the human MDA-MB-157 TNBC cell line [7]. Due to the increased incidence of chemotherapeutic resistance in tumors with mutated APC, it is essential to study the uninvestigated roles of APC and gain insight on its implications in treatment efficacy.

We hypothesized that varying microtubule stability in normal cells versus APC shRNA1 cells may lead to a difference in cell cycle protein modulators during G2/M transition. In this paper we show that there is an increased population of APC shRNA1 cells in the G2/M phase after PTX treatment compared to the PTX treated parent cells. In addition, there is a significant increase in total CDK1 and CDK6 expression in the APC shRNA1 cells. PTX treatment conferred downregulation of p27 in MDA-MB-157 and APC shRNA1 cells. RNA-sequencing showed gene expression differences in cell cycle-related transcripts between the parental and APC shRNA1 cells. GLI1, NUPR1, and LBH were confirmed to be up-regulated, while RGS4 was decreased, in untreated APC shRNA1 cells compared to untreated parental cells. These four genes play

different roles in cell cycle control and expression of cell cycle proteins, but the combined expression pattern change observed with APC knockdown suggests a connection between APC and regulation of the cell cycle. Taken together, the observation that APC controls expression of multiple cell cycle genes and proteins is important to understand the mechanism of resistance seen in APC shRNA1 cells, and provides multiple viable targets for combination therapy in PTX-resistant TNBCs.

METHODS
Cell Culture and Drug Treatment

MDA-MB-157 breast cancer cells (ATCC, Manassas, VA) were maintained at 37°C with 5% CO_2 in RPMI 1640 media with 1:5000 plasmocin, 1% penicillin/streptomycin, 10% fetal bovine serum and 25 mM HEPES. The MDA-MB-157 cells were authenticated using STR DNA profiling (Genetica DNA Laboratories, Burlington, NC). Lentiviral mediated shRNA knockdown of *APC* was performed in MDA-MB-157 cells to create the *APC* knockdown shRNA 1 and 2 cell lines [7]. The *APC* knockdown shRNA 1 and 2 cell lines were routinely maintained in media containing 1.5 µg/mL puromycin (MilliporeSigma, St Louis, MO). Cells were regularly passaged using 0.25% trypsin/EDTA. For drug treatments, cell lines treated at 50-70% confluence with 1 µM nocodazole, 0.078 µM paclitaxel, 16 µM cisplatin, or control DMSO for 24 hours. Nocodazole was used as a control for G2/M arrest, and cisplatin was used as a control because it effectively kills APC shRNA1 cells [7]. All drugs were purchased from MilliporeSigma.

Flow Cytometry

MDA-MB-157 and APC shRNA1 cells were used for each treatment: nocodazole, PTX, or control. After 24 hours of treatment, $2x10^6$ cells were fixed using dropwise addition of 70% ethanol, with vortexing between additions. Cells were fixed for 30 minutes at 4°C and then washed with PBS. Cells were centrifuged and the pellets were resuspended in RNase1 and Propidium Iodide (PI). After PI staining was performed, forward scatter and side scatter were obtained, as well as PI fluorescence, on a Cytotomics FC 500 (Beckman Coulter, Brea, CA) flow cytometer. The percentage of cells in each phase of the cell cycle was determined using FlowJo Flow Cytometry Data Analysis Software (Tree Star, Ashland, OR), using GraphPad Prism for statistical analysis. Graph shows average with error bars to illustrate standard deviation. Statistical significance was determined using one-way ANOVA with a post-hoc Sidak test.

Western Blotting

Protein was isolated from cells after 24-hour drug treatment as described above. Cells were washed with cold PBS and then 150 µL lysis buffer was added to each 10 cm plate. Lysis buffer consisted of 1 mL wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% NP-40), 1.0 mM EDTA, 0.2 mM PMSF, and 1X protease inhibitor cocktail (Fisher). For phosphorylation specific analysis, 1 ml of a phospho-enhancing lysis buffer (20 mM Tris-HCL, 150 mM NaCl, 1% Triton-X, 0.5% NP-40, 50 mM NaF, 1mM Na_3VO_4 and 5mM Sodium Pyrophosphate) was combined with 0.2 mM PMSF, 1X protease inhibitor, and 1X phosphatase inhibitor (Sigma). Cells were then incubated at 4°C for 30 minutes with shaking. The lysate was collected and spun at 15,000 rpm at 4°C for 15 minutes to pellet debris. Protein concentrations were measured using BCA Assay (ThermoFisher) as per manufacturer's instructions and stored at -80°C until further use.

Protein samples were separated using a 10% SDS-PAGE gel for cell cycle protein analysis or a BioRad Mini-PROTEAN TGX Precast 4-20% gradient gel for fractionated samples. Protein was then transferred to a 0.45um Immobilon-P PVDF membrane (Millipore). After blocking for 1 hr in 5% nonfat dried milk in TBST, membranes were incubated with primary antibody (Table 1) overnight at 4°C. Membranes were then incubated with a species-specific HRP-conjugated secondary antibody (1:1000 in the same diluent as the primary) for 1 hr at RT. Clarity or Clarity

Max ECL reagent and a ChemiDoc MP Imaging System (Bio-Rad) were used to image the blots. β-actin was used as a loading control with a 1hr RT incubation. Analysis of protein levels relative to actin were performed by densitometry using ImageJ software (NIH). The protein levels of the triplicates were averaged and graphed +/- standard deviation. For the phosphorylation sites, the value graphed was the ratio of the site expression over actin to the total CDK1 protein expression over actin.

Fractionation

MDA-MB-157 and APC shRNA1 cells were plated in 10 cm dishes, grown to 70% confluency and treated with drugs as above for 24 hours. Cells were then collected using trypsin and resuspended in PBS. After centrifugation, the pellet was collected and resuspended in 100 uL of cytoplasmic extract buffer (10mM HEPES, 60 mM KCl, 1 mM ETDA, 0.075% (v/v) NP40, 1 mM PMSF, 1mM DTT, adjusted to a pH of 7.6) and incubated on ice for three minutes. The supernatant was removed and placed in a clean tube; this was the cytoplasmic extract (CE). The remaining nuclear pellets were then carefully washed with 100 uL of cytoplasmic extract buffer without detergent (10mM HEPES, 60 mM KCl, 1 mM ETDA, 1 mM PMSF, 1mM DTT, adjusted to a pH of 7.6) and the supernatant was removed and discarded. 50 uL of the nuclear extract buffer (20 mM Tris Cl, 520 mM NaCl, 1,5 mM MgCl$_2$, 25% (v/v) glycerol, 1 mM PMSF, adjusted to pH of 8.0) and 35 uL of 5M NaCl was added to the pellet. An additional 50 uL of nuclear extract buffer was then added and the pellet was resuspended by vortexing. The nuclear extract was incubated on ice for 10 minutes with periodic vortexing. Both the cytoplasmic and nuclear extracts were spun down and the contents were transferred to clean tubes. 20% (v/v) of glycerol was added to the cytoplasmic extracts. Protein quantification was performed, samples were prepared and then analyzed using western blot. HDAC and Histone H3.3 were used as controls for nuclear fractionation.

RNA Sequencing and functional analysis

RNA-sequencing was performed to glean changes occurring in the MDA-MB-157 and APC shRNA1 cells. Control treated and chemotherapy treated cells were assessed through the Genomics Core Facility at the University of Notre Dame. For analysis, raw sequences were trimmed of adapters with Trimmomatic and assessed for quality with FastQC. Trimmed sequences were aligned to the human genome (Homo_sapiens. GRCh38), using corresponding annotations, with TopHat2 using Bowtie 2 [9, 10]. Corresponding alignments were sorted with SAMtools. Read counts were generated with HTSeq-count and were merged with a python script. The merged counts files were normalized using DESeq2 [11]. Functional analysis of the normalized data was done using topGO [12]. topGO provides a convenient means to analyze overrepresentation of GO terms in sample gene lists and gene lists associated with significance scores. The significance of different ontology categories were calculated using different statistics viz. Fisher's exact test, and Kolmogorov-Smirnov test. Genes associated with the GO terms were extracted and identified using the Bioconductor package BioMart [13]. Normalized expression data associated with these genes were used to construct a heatmaps using ggplot2 [14].

Quantitative analysis by Real-Time RT-PCR

RNA was isolated from the MDA-MB-157 and APC shRNA1 cells using Tri Reagent (Molecular Research Center, Cincinnati, OH), and cDNA synthesis was performed with iScript (Bio-Rad Laboratories, Hercules, CA). Real-time RT-PCR was performed with Power SYBR Green master mix (Applied Biosystems, Foster City, CA) and 50ng cDNA. Primer sequences are presented in Table 2. The amplification program included: 2 initial steps at 50° C for 2 minutes and 95° C for 10 minutes; 40 cycles of 95° C for 15 seconds and 60° C for 1 minute to allow for denaturation, annealing, and extension; and concluded with generation of a melt curve (CFX

Connect 96 thermal cycler, Bio-Rad). Samples were run in duplicate for three independent experiments, with GAPDH as a reference gene to normalize differing levels of expression.

Statistical analysis

Western blots were analyzed via ImageJ (NIH), and protein quantifications from triplicate runs were averaged and represented using bar graphs with error bars depicting standard deviation unless noted. Real-time RT-PCR reactions were quantified by interpreting the ratio of fluorescence to cycle number to reach threshold (Ct) as relative expression of the gene. Bar graphs of gene expression were then created by averaging biological replicates in Microsoft Excel or GraphPad Prism, and error bars were included to illustrate standard deviation unless noted. Statistical significance was determined using one-way ANOVA with a post-hoc Tukeys t-test.

RESULTS

APC shRNA1 cells have increased G2/M arrest after PTX treatment compared to MDA-MB-157 cells.

PTX is a well-established spindle poison, working by inducing apoptosis after arresting cells during mitosis. It activates the spindle assembly check point and soon after induces mitotic arrest [6]. APC is also involved in microtubule regulation, but through mechanisms that are not fully known. Therefore, flow cytometry was used to study the cell cycle profile of the MDA-MB-157 cells and APC shRNA1 cells under control and PTX treatments. Because PTX works by arresting cells during mitosis, we expected an increase in G2/M expression following PTX treatment in cells sensitive to the drug. Nocodazole was used as a positive control because it is known to induce G2/M arrest. Cell cycle analysis indicated that both cell lines exhibited an increase in the G2/M population after PTX treatment (**Figure 1**). In contrast to our hypothesis, the APC shRNA1 cells had a more robust G2/M arrest after PTX treatment compared to the PTX-treated parent cells. (**Figure 1**). This finding led us to further investigate proteins involved in the G2/M phase of the cell cycle.

Alterations of G2/M checkpoint proteins in APC shRNA1 cells.

The G2/M transition is regulated by the protein complex of CDK1 and cyclin B1. Given the increased G2/M arrest in the PTX-treated APC shRNA1 cells and the role of PTX in mitosis, we next investigated the effect of PTX and APC status on the expression of CDK1 and cyclin B1. We found that there was an increase in total CDK1 expression in the APC shRNA1 cells compared to the parental cells (**Figure 2**), while no change was observed in cyclin B1 expression. We also profiled the inhibitory (Thr^{14} and Tyr^{15}) and activating (Thr^{161}) phosphorylation sites on CDK1, and found no changes in phosphorylation patterns in the APC shRNA1 cells compared to the parental cells. We next assessed whether PTX treatment influenced the expression of cyclin B1 or CDK1, or the phosphorylation status of CDK1. Interestingly, no changes were observed after PTX treatment in either cell line (**Figure 2**).

Sub-cellular localization of G2/M checkpoint proteins in APC shRNA1 cells.

Altered expression of these checkpoint proteins led us to further explore the CDK1-cyclin B1 complex. The regulation of this complex is essential for proper cell cycle progression. The progression from the G2 phase to the M phase is dependent on the activation and nuclear localization of the CDK1-cyclin B1 complex. The destruction of this complex allows for further progression into anaphase. Because the activity of this complex is dependent on its localization

6

in the cell, we examined the expression of CDK1 and cyclin B1 in the cytoplasm and the nucleus using fractionation. Nocodazole was used as a positive control because it is known to induce G2/M arrest. Analysis showed that CDK1 was preferentially located in the cytoplasm in the untreated cell lines, while cyclin B1 had no preferential localization (**Figure 3**).

Loss of APC or PTX treatment alters expression of cell cycle proteins

Aside from the G2/M checkpoint proteins, CDK1 and cyclin B1, other proteins that regulate cell cycle dynamics, including cyclin/CDK complexes and the CKIs, p27 and p21, have been shown to impact response to taxanes [15-20]. This information led us to interrogate the effect of APC loss on the expression of different cyclins, CDKs, and other cell cycle proteins in the presence or absence of PTX. We found that the G1/S regulator, CDK6, is significantly upregulated in in APC shRNA1 cells (**Figure 4**). Interestingly, p27 expression decreased upon PTX treatment in both parental and APC shRNA1 cells (**Figure 4**). No changes were observed in the other cell cycle proteins investigated (**Figure 4**).

RNA sequencing analysis shows cell cycle related gene alterations in APC shRNA1 MDA-MB-157 cells.

Given the lack of Wnt pathway activation in the APC shRNA1 MDA-MB-157 cells (data not shown), similar to our observations in the MMTV-PyMT;*Apc^{Min/+}* cells [7], we wanted to assess global gene expression changes to understand the broad cell cycle changes observed. Therefore, we performed RNA sequencing on MDA-MB-157 parent cells and APC shRNA1 cell lines. Functional analysis of the transcriptomes of parent cells MDA-MB-157 compared to APC shRNA1 cell lines revealed among others several terms associated with cell cycle and cell division (Table 3). There were over 400 common transcripts differentially expressed between the two cell lines that were associated with cell division and/or cell cycle. A subset of transcripts among these that significantly differentially expressed are shown in the heatmap (**Figure 5A**). The entire set is available as a supplement (**Supplemental Figures S1 and S2**). Given their functions related to cell cycle phenotypes observed in the APC shRNA1 cells, we confirmed expression of: Glioma-associated oncogene/Zinc finger protein 1 (GLI1); Limb-Bud-Heart (LBH); Nuclear Protein 1 (NUPR1); and Regulator of G-protein Signaling 4 (RGS4). LBH and RGS4 were confirmed using real-time RT-PCR (**Figure 5B**) and NUPR1 and GLI1 were confirmed via western blot (**Figure 5C**). In accordance with the RNA-sequencing results, APC shRNA1 cells showed an increase in GLI1, LBH, and NUPR1 and a decrease in RGS4 expression compared to the MDA-MB-157 parental cell line (**Figure 5B and 5C**).

DISCUSSION

Paclitaxel is a β-tubulin-binding chemotherapeutic agent widely used to treat cancers of various types, including TNBC, by disrupting MT dynamics to induce mitotic arrest and apoptosis. The APC tumor suppressor is also involved in the regulation of microtubule stability through mechanisms that are not fully understood; however, the basic domain of the APC gene binds directly to β-tubulin and interacts indirectly with MTs. Although Paclitaxel's mechanism of action is well characterized, mechanisms of resistance remain vague, especially in cancers lacking APC. Since both APC and PTX bind β-tubulin, discovering mechanisms of APC-mediated PTX resistance is a priority for improved clinical outcomes. The present study examines the effect of APC status and/or PTX treatment on cell cycle progression and cell cycle protein expression, activation, and localization in MDA-MB-157 cells, specifically at the G2/M interphase. We also identify potential future targets through RNA sequencing that could have implications on cell cycle regulation and the response to PTX.

PI staining and flow cytometry showed that PTX treatment caused an increase of MDA-MB-157 and APC shRNA1 cells in the G2/M phase of the cell cycle. However, the G2/M arrest of the APC shRNA1 cells was more robust than that of the parental cells (**Figure 1**). Similar results have been found by other groups, where Taxol treated, APC-mutant embryonic stem (ES) cells accumulate in the G2/M phase ([21, 22] and reviewed in [23]). These data suggest that APC status does not prevent G2/M arrest after PTX treatment and that the mechanisms required to arrest both the parental and APC shRNA1 cells are functional, but the fate of the cell is altered. This altered state of cell fate could be due to alterations in proteins that regulate PTX-induced apoptosis, such as the Bcl-2 family of proteins. Many Bcl-2 family members, including Bcl-2, Bax, Bak, and Bcl-xL are known to impact PTX sensitivity in breast cancer [24-26]. Future studies will examine differences in expression of Bcl-2 family members to explain the robust accumulation of APC shRNA1 cells in G2/M.

The activation of the mitotic checkpoint involves the protein complex of CDK1-cyclin B1. This complex is involved in cell cycle control, with progression from the G2 to the M-phase being dependent on the activation and nuclear localization of this complex. For an active nuclear complex, CDK1 must be phosphorylated on Thr^{161} and dephosphorylated on Thr^{14} and Tyr^{15}. This active complex regulates M-phase entry and exit, and is responsible for activation of the anaphase promoting complex (APC/C) [27]. Further progression into anaphase is dependent on destruction of the active CDK1-cyclin B1 complex, which is mediated by APC/C [28]. Therefore, we analyzed the expression, activation, and subcellular localization of these important G2/M checkpoint proteins. Examination of protein expression by western blot showed upregulated levels of CDK1 in APC shRNA1 cells compared to the parental cell line (**Figure 2**). We also examined activation of CDK1 by profiling phosphorylation sites on CDK1 including the inhibitory (Thr^{14} and Tyr^{15}) and activating (Thr^{161}) phosphorylation sites, finding no significant change in CDK1 activation status between parental and APC shRNA1 cell lines (**Figure 2**). Examination of subcellular protein localization by fractionation indicated that CDK1 is preferentially located in the cytoplasm in the untreated cell lines, while cyclin B1 has no preferential localization (**Figure 3**). Since other cyclins and CDKs have been shown to mediate PTX sensitivity, as well as CDK1 activity, we also examined expression of other cell cycle proteins [15-20]. Protein expression by western blot indicated that APC shRNA1 cells have significantly increased CDK6, while PTX treatment caused a decrease in p27 expression in both cell lines (**Figure 4**). Since expression, localization, and activation of p27 have been linked to a number of tumorigenic and chemoresistant phenotypes, the loss of kinase inhibition by p27 may be driving the taxane resistance in APC shRNA1 cells [15-17, 29-31]. Activated kinases regulate tumor cell proliferation; therefore, a possible mechanism of drug resistance in tumor cells involves the positive selection for kinases that can lead to evasion of apoptotic response [32]. Targeting CDK1, either by selective inhibition or prolonged activation through Wee1 inhibition, has been successful in increasing the efficacy of PTX in breast and ovarian cancers [33, 34]. Future studies will examine the effect of CDK inhibition and localization of p27 on PTX sensitivity in MDA-MB-157 and APC shRNA1 cells.

RNA sequencing revealed 403 common transcripts between the two APC shRNA cell lines, including those involved in expression of cell cycle proteins (data not shown and **Figure 5A**). In accordance with the RNA sequencing results, RT-PCR validation showed an increase in LBH and a decrease in RGS4 expression (**Figure 5B**) and Western Blot validation demonstrated an increase in GLI1 and NUPR1 (**Figure 5C**) in APC shRNA1 cells compared to the parental cells. NUPR1 is a transcriptional regulator that is upregulated in response to cell stress and therefore is involved in many pathways including regulating the cell cycle, apoptosis, and DNA repair. It

has been shown that NUPR1 is associated with poor prognosis as well as chemoresistance in breast cancer [35-37]. An increase in NUPR1 in APC shRNA1 cells could be a possible mechanism for evading apoptosis induced by chemotherapy or arresting in G2/M. GLI1 is an effector protein of the Hedgehog (Hh) pathway, involved in cell development and differentiation. Increased expression of GLI1 has been shown to be associated with metastasis, increased proliferation, and the enrichment of cancer stem cells [38-40]. Increased transcription of cell proliferation and cell survival genes, such as cyclin D1 and Bcl-2, has been linked to the active Hh pathway [41]. Therefore, increased GLI1 could link cell cycle alteration in the APC shRNA1 cells with increased Hh pathway activity. Our lab has previously shown that APC loss-of-function results in increased tumor initiating cells (TICs) [7]. Given the role of TICs in developing drug resistance (reviewed in [42]), the increased GLI1 expression in APC shRNA1 cells could indicate an increase in TICs, leading to PTX resistance. Aside from being a key regulator in the Wnt/β-catenin pathway, LBH can regulate aspects of the cell cycle and is highly expressed in aggressive basal subtype breast cancers [35, 36]. LBH deficiency has been shown to arrest cells S phase by altering cell cycle protein expression and DNA damage repair pathways [36]. Therefore, the increased LBH (**Figure 5**) could be contributing to the cell cycle alterations observed in APC shRNA1 cells. RGS4 is a GTPase activating protein that forces G proteins into their inactive form. Studies have shown loss of RGS4 in multiple cancer types, including non-small cell lung cancer [37], melanoma [38], and breast cancer [39, 40]. RGS4 expression has been shown to decrease in response to cell stress [41], and lower cellular levels have been associated with increased proliferation and involvement with cell cycle arrest in the G2/M phase [42]. Future studies could investigate whether APC shRNA1 cells have increased proteasomal degradation of RGS4 to activate GTPases involved in anti-apoptotic pathways. Together, these genes may be intermediate molecular markers between APC status and response to PTX. Future studies will explore the impact of these gene expression changes on PTX resistance.

Our lab has found that APC mediates chemotherapeutic response in several TNBCs, including the response of MDA-MB-157 and APC shRNA1 cells to PTX. The mechanisms by which PTX and APC bind β-tubulin to effect the G2 and M phases are well characterized, but APC-mediated mechanisms of PTX resistance remain unexplored. Due to the effects of PTX treatment on G2/M arrest and the possible role APC plays in microtubule regulation, exploration of the kinases and cell cycle proteins associated with the G2/M transition may provide insight to the mechanism of PTX resistance. Examining a time course of PTX treatment for the cell cycle, targeting the kinases and genes involved in cell cycle progression indicated by RNA seq to be altered by APC status, and interrogating how APC status effects PTX binding to MTs are of upmost importance in elucidating the role of APC-mediated PTX resistance in TNBC.

Conclusions: Loss of the APC tumor suppressor in human TNBC cells alters the response to taxane treatment, likely through cell cycle mediated changes. Regulation of CDK1 and CDK6 at the protein level is dependent on APC expression. Combined, this suggests that APC status may be useful as a marker for taxane-resistant TNBC, and that targeting downstream of APC could be a novel therapeutic approach for TNBC.

REFERENCES

1.   Horwitz SB: **Taxol (paclitaxel): mechanisms of action**. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 1994, **5 Suppl 6**:S3-6.

2.   Chang YS, Lin CY, Yang SF, Ho CM, Chang JG: **Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer**. *Cancer Cell Int* 2016, **16**:23.

3.   Bahmanyar S, Nelson WJ, Barth AI: **Role of APC and its binding partners in regulating microtubules in mitosis**. *Adv Exp Med Biol* 2009, **656**:65-74.

4.   Van der Auwera I, Van Laere SJ, Van den Bosch SM, Van den Eynden GG, Trinh BX, van Dam PA, Colpaert CG, van Engeland M, Van Marck EA, Vermeulen PB *et al*: **Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype**. *British journal of cancer* 2008, **99**(10):1735-1742.

5.   Mukherjee N, Bhattacharya N, Alam N, Roy A, Roychoudhury S, Panda CK: **Subtype-specific alterations of the Wnt signaling pathway in breast cancer: clinical and prognostic significance**. *Cancer science* 2012, **103**(2):210-220.

6.   Radulescu S, Ridgway RA, Appleton P, Kroboth K, Patel S, Woodgett J, Taylor S, Nathke IS, Sansom OJ: **Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol**. *Oncogene* 2010, **29**(49):6418-6427.

7.   VanKlompenberg MK, Bedalov CO, Soto KF, Prosperi JR: **APC selectively mediates response to chemotherapeutic agents in breast cancer**. *BMC cancer* 2015, **15**:457.

8.   Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE, Zetter BR: **miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo**. *Oncogene* 2011, **30**(43):4386-4398.

9.   Langmead B, Salzberg SL: **Fast gapped-read alignment with Bowtie 2**. *Nature methods* 2012, **9**(4):357-359.

10.   Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL: **TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions**. *Genome biology* 2013, **14**(4):R36.

11.   Love MI, Huber W, Anders S: **Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2**. *Genome biology* 2014, **15**(12):550.

12.   Rahnenfuhrer AAaJ: **topGO: Enrichment Analysis for Gene Ontology**. In., 2.38.1 edn; 2019: R package.

13.   Durinck S, Spellman PT, Birney E, Huber W: **Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt**. *Nature protocols* 2009, **4**(8):1184-1191.

14.   Wickham H: **Ggplot2 : elegant graphics for data analysis**. New York: Springer; 2009.

15.   Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, Heys SD, Schofield AC: **Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells**. *Breast cancer research : BCR* 2004, **6**(5):R601-607.

16.   Schmidt M, Fan Z: **Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells**. *Oncogene* 2001, **20**(43):6164-6171.

17.   Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC, Jr.: **The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells**. *Journal of the National Cancer Institute* 2011, **103**(18):1403-1422.

18.   Takahashi T, Yamasaki F, Sudo T, Itamochi H, Adachi S, Tamamori-Adachi M, Ueno NT: **Cyclin A-associated kinase activity is needed for paclitaxel sensitivity**. *Molecular cancer therapeutics* 2005, **4**(7):1039-1046.

19.   Michalides R, Tiemessen M, Verschoor T, Balkenende A, Coco-Martin J: **Overexpression of cyclin D1 enhances taxol induced mitotic death in MCF7 cells**. *Breast cancer research and treatment* 2002, **74**(1):55-63.

20.   Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN *et al*: **Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells**. *Breast cancer research : BCR* 2009, **11**(1):R12.

21.   Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Nathke IS: **A role for the Adenomatous Polyposis Coli protein in chromosome segregation**. *Nature cell biology* 2001, **3**(4):429-432.

22.   Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH *et al*: **Mutations in the APC tumour suppressor gene cause chromosomal instability**. *Nature cell biology* 2001, **3**(4):433-438.

23.   Aoki K, Taketo MM: **Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene**. *Journal of cell science* 2007, **120**(Pt 19):3327-3335.

24.   Sharifi S, Barar J, Hejazi MS, Samadi N: **Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel**. *Asian Pac J Cancer Prev* 2014, **15**(20):8617-8622.

25.   Flores ML, Castilla C, Avila R, Ruiz-Borrego M, Saez C, Japon MA: **Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction**. *Breast cancer research and treatment* 2012, **133**(3):917-928.

26.   Dai H, Ding H, Meng XW, Lee SH, Schneider PA, Kaufmann SH: **Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance**. *Cancer research* 2013, **73**(23):6998-7008.

27.   Kraft C, Herzog F, Gieffers C, Mechtler K, Hagting A, Pines J, Peters JM: **Mitotic regulation of the human anaphase-promoting complex by phosphorylation**. *The EMBO journal* 2003, **22**(24):6598-6609.

28.   Felix MA, Labbe JC, Doree M, Hunt T, Karsenti E: **Triggering of cyclin degradation in interphase extracts of amphibian eggs by cdc2 kinase**. *Nature* 1990, **346**(6282):379-382.

29.   Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM: **Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells**. *Proceedings of the National Academy of Sciences of the United States of America* 2000, **97**(16):9042-9046.

30.   Abukhdeir AM, Park BH: **P21 and p27: roles in carcinogenesis and drug resistance**. *Expert Rev Mol Med* 2008, **10**:e19.

31.   Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS: **Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype**. *Hum Pathol* 2007, **38**(4):585-592.

32.   Greenberger L.M. SD: **Resistance To Taxanes**. In: *Cancer Drug Resistance Cancer Drug Discovery and Development* edn. Edited by B.A. T: Humana Press; 2006: 329–358.

33.   Bae T, Weon KY, Lee JW, Eum KH, Kim S, Choi JW: **Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer**. *Carcinogenesis* 2015, **36**(12):1561-1571.

34.   Lewis CW, Jin Z, Macdonald D, Wei W, Qian XJ, Choi WS, He R, Sun X, Chan G: **Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel**. *Oncotarget* 2017, **8**(43):73705-73722.

35.   Rieger ME, Sims AH, Coats ER, Clarke RB, Briegel KJ: **The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers**. *Molecular and cellular biology* 2010, **30**(17):4267-4279.

36.   Matsuda S, Hammaker D, Topolewski K, Briegel KJ, Boyle DL, Dowdy S, Wang W, Firestein GS: **Regulation of the Cell Cycle and Inflammatory Arthritis by the Transcription Cofactor LBH Gene**. *J Immunol* 2017, **199**(7):2316-2322.

37.   Cheng C, Yue W, Li L, Li S, Gao C, Si L, Tian H: **Regulator of G-protein signaling 4: A novel tumor suppressor with prognostic significance in non-small cell lung cancer**. *Biochemical and biophysical research communications* 2016, **469**(3):384-391.

38.   Xue X, Wang L, Meng X, Jiao J, Dang N: **Regulator of G protein signaling 4 inhibits human melanoma cells proliferation and invasion through the PI3K/AKT signaling pathway**. *Oncotarget* 2017, **8**(45):78530-78544.

39.   Xie Y, Wolff DW, Wei T, Wang B, Deng C, Kirui JK, Jiang H, Qin J, Abel PW, Tu Y: **Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4**. *Cancer research* 2009, **69**(14):5743-5751.

40.   Weiler M, Pfenning PN, Thiepold AL, Blaes J, Jestaedt L, Gronych J, Dittmann LM, Berger B, Jugold M, Kosch M *et al*: **Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment**. *Oncogene* 2013, **32**(9):1099-1109.

41.   Song L, Jope RS: **Cellular stress increases RGS2 mRNA and decreases RGS4 mRNA levels in SH-SY5Y cells**. *Neuroscience letters* 2006, **402**(3):205-209.

42.   Park HJ, Kim SH, Moon DO: **Growth inhibition of human breast carcinoma cells by overexpression of regulator of G-protein signaling 4**. *Oncol Lett* 2017, **13**(6):4357-4363.

Author contributions: EA performed and analyzed the data regarding CDK1 and cyclin B1 and was the primary contributor of the writing. CH performed and analyzed the data on the cell cycle proteins (cyclins, CDKs, etc). SM performed and analyzed the validation of the RNA-sequencing data. TMN analyzed the RNA-sequencing data. JP performed and analyzed the remaining experiments and was responsible for editing and writing the manuscript. All authors read and approved the final manuscript.

Competing interests: The authors declare that they have no competing interests.

Figure Legends

Figure 1. Analysis of G2/M Cell Cycle arrest under PTX in MDA-MB-157 & APC shRNA1 cells. **(A)** Cell cycle analysis of untreated and PTX treated MDA-MB-157 and APC shRNA1 cells using flow cytometry. Nocodazole was used as a positive control because it is known to induce G2/M arrest. Representative flow cytometry graphs are included. **(B)** Graphical representation of the percentage of cells in the G2/M phase of the cell cycle in control and PTX treated cells. Data shown are the average of 4 independent experiments, and the STDEV is shown. * $p < 0.05$, ** $p < 0.01$ compared to control treated cells of the same genotype.

Figure 2. Western Blots of G2/M Checkpoint Proteins. **(A)** Control and paclitaxel or cisplatin treated cell lysates were probed for expression of G2/M checkpoint proteins. Representative western blots are shown for cyclin B1 and CDK1, including the inhibitory (Thr^{14} and Tyr^{15}) and activating (Thr^{161}) phosphorylation sites on CDK1. **(B-F)** Bar graph representation of G2/M transition protein quantification in treated and untreated MDA-MB-157 and APC shRNA1 cell lines. Bar graphs show levels of cyclin B1 and CDK1, Thr^{14}, Tyr^{15} and Thr^{161} in these treated and untreated cells. For the phosphorylation sites, the value graphed was the ratio of the site expression over actin to the total CDK1 protein expression over actin (n=3). Analysis indicated an increase in total CDK1 expression in the APC shRNA1 cell line. ** $p < 0.01$ as compared to the parental cells.

Figure 3. Western Blot Analysis of Cellular Fractions. Protein lysates from control, paclitaxel or nocodazole treated cells were fractionated and then probed with CDK1 **(A and C)** or cyclin B1 **(B and D)**. HDAC and H3.3 were used as loading controls for the nuclear extract specifically, while actin was used as a widespread loading control. **(A-B)** Bar graph representation of protein quantification (n=3). **(C-D)** Representative western blots are shown. Analysis indicated that CDK1 is preferentially located in the cytoplasm in the untreated parental and APC shRNA1 cells. Cyclin B1 shows no preferential localization. ** $p < 0.01$ as compared to corresponding cytoplasmic extract. Westerns were run and membranes cut after transfer. For CDK1, the top portion was probed for HDAC (61kD), and the bottom portion was probed for CDK1 (34kD) and actin (42kD). For cyclin B1, the top portion was probed for cyclin B1 (55kD) and actin (42kD), and the bottom was probed for Histone H3.3 (15kD).

Figure 4. Western Blot Analysis of Canonical Cell Cycle Proteins. Control or paclitaxel treated lysates were probed for expression of canonical cell cycle proteins. **(A)** Representative western blots are shown for cyclin A2, cyclin E1, cyclin D1, cyclin D3, CDK2, CDK4, CDK6, p18, p21, and p27. Actin was used as a loading control. **(B-C)** Bar graph of protein expression quantification in treated and untreated MDA-MB-157 and APC shRNA1 cell lines is shown (n=3). **(B)** Analysis indicated that loss of APC resulted in a significant increase in CDK6 expression. * $p < 0.05$ compared to parental cells. **(C)** P27 expression was decreased upon PTX treatment in both MDA-MB-157 and APC shRNA1 cells. * $p < 0.05$, *** $p < 0.001$ compared to control treated cells of the same genotype. No change was seen in the remaining proteins.

Figure 5. RNA sequencing and validation of APC shRNA1 cells compared to parental controls. (A) Hierarchical clustering and heat map of significantly differentially expressed genes associated with the cell cycle. Input data are the normalized expression values. The values in blue are up-regulated and those in red are down-regulated. **(B)** Real-time RT-PCR analysis for LBH and RGS4 in MDA-MB-157 and APC shRNA1 cells. Data were initially normalized by amount of GAPDH mRNA, and then further normalized to the parental cells. Data (AVG +/- SEM) depict changes in expression between parental and APC shRNA1 cells, with average of parental (n=3) set to 1 and average of APC shRNA1 representing fold-change. **(C)** Western blot analysis for GLI1 and NUPR1 in MDA-MB-157 and APC shRNA1 cells with Actin as a loading

control. Bar graph representation of protein quantification (n=3 for GLI1 and n=4 for NUPR1) in untreated and PTX treated cells. Analysis indicated that loss of APC increased GLI1 and NUPR1 in untreated cells. * p < 0.05, ** p < 0.01 as compared to parental cells.

Supplemental Figure S1. Heat map and gene description for genes down-regulated in the APC shRNA1 cells. (A) Hierarchical clustering and heat map of the genes associated with the over-represented biological process ontologies of cell cycle/cell division. Input data are the normalized expression values. The values in blue are upregulated and those in red are down-regulated. **(B)** The description of each gene in the clusters are available from the associated excel file.

Supplemental Figure S2. Heat map and gene description for genes up-regulated in the APC shRNA1 cells. (A) Hierarchical clustering and heat map of the genes associated with the over-represented biological process ontologies of cell cycle/cell division. Input data are the normalized expression values. The values in blue are upregulated and those in red are down-regulated. **(B)** The description of each gene in the clusters are available from the associated excel file.

Table 1. Antibody information for western blots.

| Antibody	Dilution	Diluent	Source
Cyclin A2	1:200	5% NFDM	Cell Signaling Technology (CST)
Cyclin B1	1:1000	5% BSA	CST
Cyclin D1	1:1000	5% BSA	CST
Cyclin D3	1:2000	5% NFDM	CST
Cyclin E1	1:1000	5% NFDM	CST
CDK1	1:1000	5% NFDM	CST
CDK1 Thr^{14}	1:1000	5% BSA	CST
CDK1 Tyr^{15}	1:1000	5% BSA	CST
CDK1 Thr^{161}	1:1000	5% BSA	CST
CDK2	1:1000	5% BSA	CST
CDK4	1:1000	5% BSA	CST
CDK6	1:2000	5% NFDM	CST
p18	1:1000	5% NFDM	CST
p21	1:1000	1% BSA	Proteintech
p27	1:1000	5% BSA	CST
HDAC	1:1000	5% BSA	CST
Histone H3.3	1:1000	5% NFDM	Abcam
β-actin	1:25,000	5% BSA or 5% NFDM	Sigma
NUPR1	1:300	5% NFDM	Proteintech
GLI1	1:1000	5% NFDM	CST

Table 2. Primer Sequences for RT-PCR

RGS4 – Forward	5' GCA GGC ATG TGA AGG AGA AAC 3'
RGS4 – Reverse	5' TAT AAG CCC GGC AGC ATA CA 3'
LBH – Forward	5' TCA CTG CCC CGA CTA TCT G 3'
LBH – Reverse	5' GGT TCC ACC ACT ATG GAG G 3'

Table 3. Over-represented biological process ontologies of cell cycle/cell division associated with the transcriptome.

Sr. No	GO.ID	Term	Annotated	Significant	Expected	Rank in classic KS	P-value classic Fisher	P-value classicKS	P-value elimKS
1	GO: 0051301	cell division	539.00	56.00	90.72	99.00	1.00	7.50E-13	6.70E-10
2	GO: 0010972	negative regulation of G2/M transition o...	79.00	6.00	13.30	273.00	0.99	1.30E-05	0.00014
3	GO: 0010971	positive regulation of G2/M transition o...	26.00	0.00	4.38	433.00	1.00	0.00025	0.00025
4	GO: 0070317	negative regulation of G0 to G1 transiti...	39.00	2.00	6.56	470.00	0.99	0.0004	0.0004
5	GO: 0010389	regulation of G2/M transition of mitotic...	176.00	13.00	29.62	126.00	1.00	2.90E-10	0.00066
6	GO: 0000079	regulation of cyclin-dependent protein s...	91.00	8.00	15.32	540.00	0.99	0.00069	0.00069
7	GO: 0044772	mitotic cell cycle phase transition	513.00	40.00	86.34	52.00	1.00	1.20E-17	0.00098
8	GO: 0007094	mitotic spindle assembly checkpoint	32.00	0.00	5.39	608.00	1.00	0.0011	0.0011

Figure 1

A

B

Figure 2

Figure 3

Figure 4

Figure 5